Memantin

Memantin
(IUPAC) ime
	3,5-dimetiltriciklo[3.3.1.13,7]dekan-1amin; ili; 3,5-dimetiladamantan-1-amin
Klinički podaci
Robne marke	Namenda
AHFS/Drugs.com	Monografija
MedlinePlus	a604006
Identifikatori
CAS broj	19982-08-2
ATC kod	N06DX01
PubChem	4054
DrugBank	DB01043
ChemSpider	3914
UNII	W8O17SJF3T
KEGG	D08174
ChEMBL	CHEMBL807
Hemijski podaci
Formula	C12H21N
Mol. masa	179,3 g/mol
SMILES	eMolekuli & PubHem
InChI
	InChI=1S/C12H21N/c1-10-3-9-4-11(2,6-10)8-12(13,5-9)7-10/h9H,3-8,13H2,1-2H3 ; Key: BUGYDGFZZOZRHP-UHFFFAOYSA-N
Farmakokinetički podaci
Bioraspoloživost	~100%
Metabolizam	Hepatički (<10%)
Poluvreme eliminacije	60–100 sati
Izlučivanje	Renalno
Farmakoinformacioni podaci
Licenca	EU EMEA:link, US FDA:link
Trudnoća	?
Pravni status	S4 (Au), POM (UK), ℞-only (U.S.)
Način primene	Oralno

Memantin je lek iz adamantanske klase lekova za tretiranje Alchajmerove bolesti| koji deluje na glutamatergični sistem putem blokiranja NMDA glutamatnih receptora. On je prvi put sintetisan u kompaniji Eli Lili 1968. Memantin je u prodaju pod imenima Aksura, Akatinol, Namenda, Ebiksa, Abiksa i Memoks. Uprkos dugogodišnjeg istraživanja, postoji malo dokaza da ima uticaja na blagu do umerene Alchajmerovu bolest.^[6]

Reference

↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit
↑ Joanne Wixon, Douglas Kell (2000). „Website Review: The Kyoto Encyclopedia of Genes and Genomes — KEGG”. Yeast 17 (1): 48–55. DOI:10.1002/(SICI)1097-0061(200004)17:1<48::AID-YEA2>3.0.CO;2-H.
↑ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594. edit
↑ Schneider, LS; Dagerman, KS, Higgins, JP, McShane, R (2011). „Lack of evidence for the efficacy of memantine in mild Alzheimer disease.”. Archives of neurology 68 (8): 991–8. PMID 21482915.

Literatura

Lipton SA (2005). „The molecular basis of memantine action in Alzheimer's disease and other neurologic disorders: low-affinity, uncompetitive antagonism”. Current Alzheimer research 2 (2): 155–65. DOI:10.2174/1567205053585846. PMID 15974913.

Vidi još

Antagonist NMDA receptora

Spoljašnje veze

	Portal Medicina
	Portal Hemija

Namenda websajt

[1] Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit

[2] Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.

[3] Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit

[4] Joanne Wixon, Douglas Kell (2000). „Website Review: The Kyoto Encyclopedia of Genes and Genomes — KEGG”. Yeast 17 (1): 48–55. DOI:10.1002/(SICI)1097-0061(200004)17:1<48::AID-YEA2>3.0.CO;2-H.

[5] Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594. edit

[Review11-6] Schneider, LS; Dagerman, KS, Higgins, JP, McShane, R (2011). „Lack of evidence for the efficacy of memantine in mild Alzheimer disease.”. Archives of neurology 68 (8): 991–8. PMID 21482915.

[1]

[2]

[3]

[4]

[5]

[6]